Projects

Operating units

omnio_healer

dermagen
A pioneer company in combating inflammatory diseases Using our natural defenses to create unique pharmaceuticals
Omnio Healer AB develops novel drug candidates based on a series of conceptual breakthroughs in inflammation research. The founding research opens up a completely new therapeutic strategy in wound healing and anti-infection. To rapidly reach a clinical proof of concept, otology have been selected as the niche field. Omniohealers’ main project is in late preclinical stage and aims to move into clinical development within the next two years. DermaGen develops therapies and formulations based on novel anti-microbial peptides (AMPs) for the treatment and prevention of bacterial and fungal infections including atopic dermatitis, impetigo and infected wounds and burns.
more_btn more_btn

pharmasurgics

lipopeptide
First-in-class pharmaceutical for prevention of post-surgical adhesions Healing hard-to-heal wounds naturally
PharmaSurgics is a clinical stage company developing treatments for improved wound healing and reduced scar formation. The products constitute patented pharmaceutical com-pounds derived from the human protein lactoferrin having a combined anti-inflammatory and anti-microbial mechanism of action. Lipopeptide AB is based on groundbreaking research on the endogenous peptide LL-37 and its capability to heal hard-to-heal-wounds. A novel product concept covered by international patents and patent applications has been developed and clinical evaluation is planned to start in Q1 2010.
more_btn more_btn

Minority interests

biocis_pharma

 
Novel pharmaceuticals and chemical sun protection products
Biocis Pharma is a clinical stage company targeting unmet medical needs in substantial therapeutic markets including inflammation, allergy and cancer. The first products are being developed for dermal and local use. A clinical phase II study is ongoing.
more_btn